Munich, Germany

Ingrid Schuster


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Ingrid Schuster and her Contributions to Antibody Development

Introduction: Ingrid Schuster, an accomplished inventor based in Munich, Germany, has made significant contributions to the field of biotechnology with a focus on antibody development. With a portfolio of six patents, her innovations are paving the way for advancements in therapeutic applications, particularly in the treatment of diseases related to osteoclast activity.

Latest Patents: Among her latest inventions, two patents stand out. The first is titled "Collection and Methods for Its Use," which details a method for enabling collections of variable heavy chain and variable light chain pairs. These collections include germline protein sequences that are pre-selected for functional properties relevant to developability. This innovation plays a crucial role in the selection process against specific antigens, employing techniques such as phage display. The second patent, "Antibody Targeting Osteoclast-Related Protein Siglec-15," describes an isolated antibody capable of binding to Siglec-15. This antibody inhibits osteoclast formation and/or osteoclastic bone resorption. It details specific sequences for the heavy and light chains of the antibody, ensuring high specificity and effectiveness in targeting.

Career Highlights: Ingrid has built a remarkable career while working with esteemed organizations such as MorphoSys AG and the Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt. Her experience in these companies has allowed her to hone her skills in antibody technology and innovation.

Collaborations: Throughout her career, Ingrid has collaborated with notable individuals in the field, including her colleagues Stefanie Urlinger and Thomas Tiller. Their combined efforts have greatly contributed to advancements in the biotechnology sector, showcasing the power of collaboration in innovation.

Conclusion: Ingrid Schuster's dedication to advancing biotechnology through her patents and collaborative efforts underscores her role as a key innovator in the field. Her work in antibody development not only reflects her expertise but also demonstrates the potential for significant medical breakthroughs in the future. As the biotech industry continues to evolve, inventors like Ingrid will be at the forefront, driving innovation and improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…